

A 24-week trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules once daily in adult participants with severe chronic hand eczema

Submission date 21/01/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/03/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/12/2023	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Chronic hand eczema (CHE) is a serious inflammatory skin disorder located anywhere on the hands or wrists. It is characterised by erythema (rash), hyperkeratosis (thickening of the outer layer of skin) and oedema (swelling). CHE is generally difficult to treat and presents with periods of flares and remissions. As the currently available treatment options either lack documented treatment effect or are limited by restrictions of long-term use due to safety concerns, there is a high unmet medical need for new topical treatments of moderate to severe CHE, especially for long-term use. New and better treatments would potentially improve the everyday lives of patients with moderate to severe CHE.

This study will compare the effectiveness, safety and affect on general health status and quality of life of delgocitinib cream and alitretinoin capsules for treating patients with CHE.

Delgocitinib, an experimental medication, is a pan JAK inhibitor (blocks specific processes, such as immune pathways, in the body's response to conditions like hand eczema). Alitretinoin is the only approved product specifically indicated for treatment of CHE, but it is only indicated for severe CHE and only approved in a few countries worldwide.

Who can participate?

Adults over 18 years, with severe CHE.

What does the study involve?

This study is randomised, which means that which of these two medications participants will receive is chosen at random. A computer will randomly select participant's treatment. Participants will have a 50% chance of receiving any one of these medications. Participants assigned to receive delgocitinib will apply delgocitinib cream to the skin twice a day for 16 weeks. Participants assigned to receive Alitretinoin will take Alitretinoin by mouth once a day for 12 weeks. All participants may continue on treatment for up to 24 weeks if the doctor considers that they are benefiting from the treatment.

What are the possible benefits and risks of participating?

There is no guarantee that participants will benefit from the treatment they get during the study. Participants are being asked to take part because the study medication may improve the symptoms of their hand eczema. The information collected in this study may help to make delgocitinib cream available for people with hand eczema in the future.

Delgocitinib cream

Based on data from studies so far, no specific side effects have been confirmed for delgocitinib cream. As for other treatments applied to the skin, participants may experience local skin reactions, for example pain where delgocitinib cream was applied. Since delgocitinib has an effect on the immune system, a risk for local skin infection and acne like lesions could arise from use of delgocitinib cream.

Alitretinoin

As alitretinoin is already approved for the treatment of severe chronic hand eczema, some side effects have been confirmed. Please be aware that some of the side effects can depend on the dose of the medication and may improve by reducing the dose. This will be decided as necessary during study conduct by the study doctor.

Where is the study run from?

Guy's and St Thomas' NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

January 2022 to December 2023

Who is funding the study?

Leo Pharma (Denmark)

Who is the main contact?

Dr Richard Woolf, Richard.Woolf@gstt.nhs.uk

Contact information

Type(s)

Principal Investigator

Contact name

Dr Richard Woolf

Contact details

Great Maze Pond

London

United Kingdom

SE1 9RT

+44 2071886410

Richard.Woolf@gstt.nhs.uk

Type(s)

Scientific

Contact name

Ms Kirsty Tunna

Contact details

The Quays, 101-105 Oxford Road
Uxbridge
United Kingdom
UB8 1LZ
+44 (0)1895 614727
kirsty.tunna@parexel.com

Additional identifiers

EudraCT/CTIS number

2021-003543-16

IRAS number

1004431

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

LP0133-1528, IRAS 1004431, CPMS 51060

Study information

Scientific Title

A 24-week, randomised, assessor-blinded, active-controlled, parallel-group, phase 3, 2-arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules once daily in adult participants with severe chronic hand eczema

Acronym

DELTA FORCE

Study objectives

1. To compare the efficacy and health-related quality of life of twice-daily topical application of delgocitinib cream with once-daily oral administration of alitretinoin capsules in the treatment of patients with severe CHE.
2. To compare the safety of twice-daily topical application of delgocitinib cream with once-daily oral administration of alitretinoin capsules in the treatment of patients with severe CHE.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 04/03/2022, South Central – Berkshire B Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 207 104 8253; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0033

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Severe hand eczema

Interventions

Eligible participants will be randomised in a 1:1 ratio to receive 1 of the following treatments:

- Topical administration of delgocitinib cream 20 mg/g, twice-daily until week 16, which may continue up to week 24 depending on clearance status (IGA-CHE score) and clinical benefit
- Oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily until week 12, which may continue up to week 24 depending on clearance status (IGA-CHE score) and clinical benefit

Randomisation will be stratified by subtype (hyperkeratotic/non-hyperkeratotic) and region (North America/Europe) and performed online.

For each participant, the trial will last at least 25 weeks and up to 33 weeks, including:

- A screening period of 1 to 4 weeks
- A treatment period of up to 24 weeks
- A safety follow up period of 2 to 5 weeks (1 visit for all participants 2 weeks after last IMP dose, plus a pregnancy follow up visit for women of childbearing potential [WOCBP] treated with alitretinoin 5 weeks after the last IMP dose)

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Delgocitinib, alitretinoin

Primary outcome measure

Hand Eczema Severity Index (HECSI) score at baseline and week 12

Secondary outcome measures

1. HECSI-90 (at least 90% improvement in HECSI score from baseline) at Week 12
2. Investigator's Global Assessment for chronic hand eczema© treatment success (IGA-CHE TS)

at Week 12

3. Change in Hand Eczema Symptom Diary© (HESD) itch score (weekly average) from baseline to Week 12
4. Change in HESD pain score (weekly average) from baseline to Week 12
5. AUC of HECSI-90 from baseline up to Week 24
6. AUC of change from baseline in Dermatology Life Quality Index (DLQI) score up to Week 24
7. Change in HECSI score from baseline to Week 24
8. Number of treatment-emergent AEs from baseline up to Week 26 measured using patient records
9. Number of treatment-emergent SAEs from baseline up to Week 26 measured using patient records
10. Number of AEs leading to IMP discontinuation up to Week 24 measured using patient records

Overall study start date

12/01/2022

Completion date

05/12/2023

Eligibility

Key inclusion criteria

1. Participant must be at least 18 years of age inclusive, at the time of signing the informed consent
2. Diagnosis of CHE defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months
3. Disease severity graded as severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 4)
4. Documented recent history of inadequate response to treatment with TCS (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable
5. Participant is adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens
6. Contraceptive use must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

510

Total final enrolment

513

Key exclusion criteria

Exclusion Criteria

Participants are excluded from the trial if any of the following criteria apply:

Diagnostic Assessments

1. Concurrent skin diseases on the hands (e.g. tinea manuum).
2. Active atopic dermatitis requiring medical treatment in regions other than the hands and feet.
3. Active psoriasis on any part of the body.
4. Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
5. Clinically significant infection (e.g. impetiginised hand eczema) on the hands.

Medical Conditions

6. Participants who cannot receive alitretinoin for any of the following reasons:
 - 6.1. Hepatic impairment, defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values $>2\times\text{ULN}$, and/or prothrombin international normalised ratio (INR) $>1.5\times\text{ULN}$.
 - 6.2. Renal insufficiency, defined as creatinine clearance $<60\text{ mL/min}$ calculated by use of the Cockcroft-Gault formula.
 - 6.3. Uncontrolled hypercholesterolemia, defined as fasting cholesterol $>1.5\times\text{ULN}$ and/or fasting low-density lipoprotein (LDL) cholesterol $>1.5\times\text{ULN}$.
 - 6.4. Uncontrolled hypertriglyceridemia, defined as fasting triglyceridaemia $1.5\times\text{ULN}$.
 - 6.5. Uncontrolled hypothyroidism, defined as thyroid stimulating hormone $>1\times\text{ULN}$ and/or thyroxine $<1\times$ lower limits of normal.
 - 6.6. Hypervitaminosis A, defined as retinol levels $>1\times\text{ULN}$ (e.g. due to the use of vitamin A supplements containing $>2000\text{ IU}$).
 - 6.7. Known or suspected hypersensitivity either to alitretinoin, to other retinoids or to any of the excipients listed in the applicable alitretinoin label, in particular allergies to peanut or soya, or intolerance to sorbitol or fructose.
 - 6.8. Any other contraindication to receive alitretinoin according to the investigator's judgement.
7. Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with the evaluation of the IMP, or reduce the participant's ability to participate in the trial. Clinically significant infections are defined as:
 - 7.1. A systemic infection.
 - 7.2. A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
8. History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
9. Major surgery within 8 weeks prior to baseline, or planned in-patient surgery or hospitalisation during the trial period.
10. History of cancer except the following:
 - 10.1. Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to screening.
 - 10.2. Participants who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.
11. Psychiatric disorders within the last year (e.g. depression, depression aggravated, anxiety, aggressive tendencies, mood alterations, psychotic symptoms, suicidal ideation, suicide attempts) or current self-reported depression or mood disturbance.

12. Any disorder that is not stable and could:

12.1. Affect the safety of the participant throughout the trial.

12.2. Impede the participant's ability to complete the trial.

Examples include but are not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, and immunological disorders, and major physical impairment.

13. Any abnormal finding that may:

13.1. Put the participant at risk because of their participation in the trial.

13.2. Influence the participant's ability to complete the trial.

The abnormal finding must be clinically significant and observed during the screening period.

Examples include abnormal findings in physical examination, vital signs, electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis.

14. Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody serology at screening.

15. Current or recent history of chronic alcohol or drug abuse or any condition associated with poor compliance as judged by the investigator.

Prior/Concomitant Therapy

16. Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).

17. Use of tanning beds, phototherapy (e.g. UVB, UVA1, PUVA), or bleach baths on the hands within 28 days prior to baseline.

18. Previous or current treatment with JAK inhibitors (including delgocitinib/LEO 124249), systemic or topical.

19. Cutaneously applied treatment with immunomodulators (e.g. PDE-4 inhibitors, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline.

20. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.

21. Other transdermal and cutaneously applied therapy on the hands (except for the use of participant's own emollients) within 7 days prior to baseline.

22. Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern, within 7 days prior to baseline.

23. Treatment with any marketed biological therapy or investigational biologic agents (including immunoglobulin, anti-IgE, and dupilumab), except vaccines:

23.1. Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.

23.2. Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.

24. Treatment with CYP3A4 inhibitors (e.g. ketoconazole), potent CYP2C9 inhibitors (e.g. fluconazole, miconazole, oxandrolone), or potent CYP2C8 inhibitors (e.g. gemfibrozil), CYP2C8 substrates (e.g. amiodarone, paclitaxel, rosiglitazone, repaglinide), simvastatin, or tetracyclines within 7 days prior to screening. Topical treatment with CYP2C9 inhibitors (e.g. fluconazole, miconazole, oxandrolone) on areas of the body other than hands is allowed.

25. Treatment with any marketed therapy that may interfere with the trial objective.

Prior/Concurrent Clinical Trial Experience

26. Previously used alitretinoin or participated in a clinical trial with alitretinoin or delgocitinib.

27. Treatment with any non-marketed drug substance (that is, an agent that has not yet been made available for clinical use following registration) within the last 28 days prior to baseline or 5 half-lives, whichever is the longest.

28. Current participation in any other interventional clinical trial.

Other Exclusions

29. Known or suspected hypersensitivity to any component(s) of the IMPs, including allergies to

peanut or soya.

30. Women who are pregnant or lactating.

31. Employees of the trial site or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.

32. Participants who are legally institutionalised.

33. Previously randomised in this clinical trial.

Date of first enrolment

10/03/2022

Date of final enrolment

26/05/2023

Locations

Countries of recruitment

Austria

Canada

France

Germany

Italy

Poland

Spain

United Kingdom

Study participating centre

Guys Hospital

Guy's and St Thomas' NHS Foundation Trust

Great Maze Pond

London

United Kingdom

SE1 9RT

Study participating centre

Queens Medical Centre

Nottingham University Hospitals NHS Trust

Derby Road

Nottingham

United Kingdom

NG7 2UH

Sponsor information

Organisation

Leo Pharma (Denmark)

Sponsor details

Industriparken 55

Ballerup

Denmark

2750

+45 53599323

fmedk@leo-pharma.com

Sponsor type

Industry

Website

<https://www.leo-pharma.com/>

ROR

<https://ror.org/05tzrdd39>

Funder(s)

Funder type

Industry

Funder Name

LEO Pharma

Results and Publications

Publication and dissemination plan

Peer reviewed scientific journals

Internal report

Conference presentation

Publication on website

Other publication

Submission to regulatory authorities

Intention to publish date

05/12/2024

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No